Allergy Injection for Humans: This Is About SCIT for People, Not Cytopoint for Dogs

No. Cytopoint (lokivetmab) is a caninized anti-IL-31 monoclonal antibody manufactured by Zoetis for treating canine atopic dermatitis in dogs. It is not FDA-approved for human use, has not been tested in humans in a clinical-trial context, and cannot be prescribed to human patients. Humans who are allergic to dogs or cats do not receive Cytopoint — they are candidates for human SCIT (CPT 95117), sublingual immunotherapy, or allergen avoidance strategies. The confusion arises because both Cytopoint (for the dog) and SCIT (for the human owner) may be relevant in a household with a dog-allergic owner and a dog with atopic dermatitis.

The standard allergy injection for humans is subcutaneous immunotherapy (SCIT) — the 3-to-5-year course of escalating subcutaneous allergen extract injections per Cox 2011 PP3. For insurance billing, the procedure is coded as CPT 95115 (single injection per visit), CPT 95117 (two or more injections per visit), and CPT 95165 (extract preparation, per dose). In clinical shorthand, the procedure is also called 'allergy shots,' 'allergen immunotherapy,' or historically 'desensitization shots.' The extracts come from FDA-licensed manufacturers (Greer, ALK-Abelló, HollisterStier); there is no branded finished-drug SCIT product.

No. Human SCIT and veterinary allergen-specific immunotherapy (vet ASIT) are different products for different species, prepared by different manufacturers under different regulatory frameworks. Human SCIT uses FDA-licensed allergen extracts per ACAAI mixing protocols. Veterinary ASIT uses separate allergen preparations from veterinary laboratories per AVMA/ACVD standards. Beyond the extract formulation difference, the two procedures cannot be interchanged — using veterinary products in humans or vice versa would be outside any approved indication and potentially dangerous.

Yes. Human SCIT is effective for pet-allergic patients. Cat dander SCIT has the strongest evidence: FDA-standardized cat hair extract (Greer license #308, 10,000 BAU/mL) with Alvarez-Cuesta 1994 JACI, Varney 1997 Clin Exp Allergy, and Lent 2006 JACI RCTs showing approximately 70-72% symptom reduction. Dog SCIT evidence is weaker — Smith 2016 review described evidence as 'poor and conflicting,' partly due to extract standardization challenges with multiple Can f allergens. Before starting pet-allergen SCIT, a specific component test for Can f 5 (dog prostate allergen) may identify the approximately 16.5% of dog-sensitized patients who are monosensitized to Can f 5 — those patients can adopt a female or neutered dog and potentially avoid SCIT entirely.

Human SCIT is traditionally administered in a physician's office with immediate epinephrine available and a 30-minute post-injection observation per Cox 2011 PP3, under a board-certified allergist overseeing the program. For eligible maintenance patients, that allergist oversight now extends to the home: Curex delivers the same SCIT as one weekly self-administered shot for $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Primary care physicians can also administer maintenance injections under protocols from the prescribing allergist, but the initial evaluation, testing, extract preparation, and build-up supervision require allergist oversight either way. Access has historically been geographically limited — Wu I et al (AAAAI 2019) found 82% of US counties have zero board-certified allergists — which is exactly why telemedicine plus Zoom-supervised at-home dosing has expanded access for eligible patients.